Sorafenib can resist tumor by inhibiting the expression of CD31, alphaSMA, pERK, VEGF, PDGF, TNFalpha, eNOS and HIF-1α/SLC7A11, BRAF/MAPK signaling pathways. Here, SLC7A11 is linked to neoplasm.